
Saadvik Raghuram Y/LinkedIn
May 26, 2025, 18:47
Saadvik Raghuram Y: A Randomized Trial of Afatinib vs Chemotherapy in NSCLC
Saadvik Raghuram Y, Head of Department of Medical Oncology at Arete Hospitals, shared a post on X:
“Now a randomized trial of Afatinib vs Chemotherapy in NSCLC With Uncommon Activating EGFR Mutations
-
Exclusions: T790M; Exon 20 insertions
-
mPFS 10.6 vs 5.7 mo favoring AFATINIB
-
ORR 62% vs 56% favouring AFATINIB.”
More posts featuring Saadvik Raghuram Y.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 26, 2025, 18:47
May 26, 2025, 16:27
May 26, 2025, 16:02
May 26, 2025, 15:37